Business
Medexus Announces Fiscal Q2 2026 Results, Driven by Strong Year-To-Date Product-Level Performance of GRAFAPEX (treosulfan) for Injection
Management to host conference call at 8:00 AM Eastern time on Thursday, November 13, 2025 Toront...
About this update from Medexus Pharmaceuticals Inc.
[{"type":"text","content":"Medexus Announces Fiscal Q2 2026 Results, Driven by Strong Year-To-Date Product-Level Performance of GRAFAPEX (treosulfan) for InjectionManagement to host conference call at 8:00 AM Eastern time on Thursday, November 13, 2025Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - November 12, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today announced its operating and financial results and provided a business update for the company's second fiscal quarter ended September 30, 2025 (the company's fiscal Q2 2026). All dollar amounts in this press release are in United States dollars unless specified otherwise.Key business updateMedexus is currently focused on delivering strong performance from GRAFAPEX™ (treosulfan) for Injection. For the three- and six-month periods ended September 30, 2025, Medexus recognized product-level net revenue from GRAFAPEX of $3.1 million and $6.2 million, relative to $3.0 million and $6.0 million of GRAFAPEX personnel and infrastructure investments. Medexus also remains focused on delivering strong overall performance across the company's portfolio of products in both the United States and Canada.\"Product-level performance of GRAFAPEX to date has exceeded our expectations, with October 2025 representing the strongest month of patient demand we have seen since our February 2025 launch,\" commented Ken d'Entremont, Chief Executive Officer of Medexus. \"The $6.0 million we have invested in the GRAFAPEX launch through September 30 is already having a significant impact. As of today, we have engaged with 83% of all 180 US transplant centers, 29% of US transplant centers have already ordered GRAFAPEX for procedures in their institutions, and 69% of those 52 institutions have reordered. We are confident that GRAFAPEX will be accretive to quarterly operating cash flows by calendar Q4 2025, which is our fiscal Q3 2026 — demonstrating that the infrastructure we have built will be a solid foundation supporting the product for years to come.\"Financial highlightsKey financial highlights for fiscal Q2 2026 include the following:Net revenue of $24.7 million and $49.4 million for the three- and six-month periods ended September 30, 2025, a decrease of $1.6 million and $4.2 million, or 6.1% and 7.8%, compared to $26.3 million and $53.6 million for the corresponding prior year periods. Th...